John Overdeck’s Mangoceuticals MGRX Stock Holding History

John Overdeck’s Portfolio MGRX Stock Details MGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,807	Closed	-$49.6K	–	3108
2023 Q2	$49.6K	Buy	+1,807	New	+$35.6K	﹤0.01%	2833

Other funds holding MGRX

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

DGAM

Desjardins Global Asset Management Montreal, Quebec, Canada $930M AUM 31.76% 1-Year Est. Return

Vanguard Capital Wealth Advisors Denver, Colorado $148M AUM 91.21% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

John Overdeck's MGRX Position: Q3 2023 in Review

John Overdeck sold out of Mangoceuticals (MGRX) in Q3 2023, closing a stake of 1,807 shares — an estimated $49.6K sold.

John Overdeck first reported a position in MGRX in Q2 2023 and held it in 1 quarter. The position peaked at $49.6K in Q2 2023. 9 funds tracked by Wall St. Rank hold MGRX as of Q3 2023.

John Overdeck reported no remaining Mangoceuticals position as of Q3 2023 after selling out during the quarter.
John Overdeck sold 1,807 Mangoceuticals shares in Q3 2023, an estimated $49.6K.
John Overdeck first reported a position in Mangoceuticals in Q2 2023 and held it in 1 quarter.
John Overdeck's Mangoceuticals position peaked at $49.6K in Q2 2023.
9 funds tracked by Wall St. Rank held Mangoceuticals as of Q3 2023.

Based on Two Sigma Investments's 13F filing for Q3 2023, filed 14 Nov 2023.